Software-guided multi-immunotherapy for solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new software-guided approach to deliver multiple immunotherapy drugs directly into the liver for people with solid tumors. It aims to see if this method can shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of a solid tumor cancer (like lung, liver, or colon) from a biopsy or other test.
- You need to be 18 or older and your doctor expects you to live at least 3 more months.
- Your liver function must be good enough (Child-Pugh class A or B, with a score of 7 or better).
- Recent blood tests must show adequate levels of white blood cells, red blood cells, and platelets, and your kidneys and clotting should be working well.
- You should not have another cancer, fluid in your belly, or serious uncontrolled health problems like heart disease or diabetes.
- You must be willing to use birth control (if applicable) and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
This trial tests a combination of immunotherapy drugs (checkpoint inhibitors) delivered directly into the liver along with standard treatment, as a first option for people with inoperable lung cancer. It aims to see if this approach can help shrink tumors and improve outcomes.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.